Jonathan Root - Nov 9, 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc. (EFTR)

Role: Director, 10%+ Owner
Signature: Dale Holladay, Attorney in Fact for the Reporting Person
Stock symbol: EFTR
Transactions as of: Nov 9, 2021
Transactions value $: -$917,006
Form type: 4
Date filed: 11/12/2021, 04:53 PM
Previous filing: Oct 8, 2021
Next filing: Nov 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EFTR	Common Stock	Sale	-$307K	-27.9K	-0.6%	$11.00	4.64M	Nov 9, 2021	Directly owned by USVP X	F1, F2
transaction	EFTR	Common Stock	Sale	-$9.83K	-893	-0.6%	$11.00	149K	Nov 9, 2021	Directly owned by AFF X	F1, F2
transaction	EFTR	Common Stock	Sale	-$344K	-32.9K	-0.71%	$10.44	4.61M	Nov 10, 2021	Directly owned by USVP X	F1, F2
transaction	EFTR	Common Stock	Sale	-$11K	-1.05K	-0.71%	$10.44	148K	Nov 10, 2021	Directly owned by AFF X	F1, F2
transaction	EFTR	Common Stock	Sale	-$121K	-11.6K	-0.25%	$10.37	4.6M	Nov 11, 2021	Directly owned by USVP X	F1, F2
transaction	EFTR	Common Stock	Sale	-$3.87K	-373	-0.25%	$10.37	147K	Nov 11, 2021	Directly owned by AFF X	F1, F2
transaction	EFTR	Common Stock	Sale	-$117K	-11.6K	-0.25%	$10.07	4.59M	Nov 12, 2021	Directly owned by USVP X	F1, F2
transaction	EFTR	Common Stock	Sale	-$3.75K	-372	-0.25%	$10.07	147K	Nov 12, 2021	Directly owned by AFF X	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4
F2	Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X with additional rights with respect to the Issuer securities, and may be deemed to have sole voting and dispositive power with respect to the shares. The Reporting Person disclaims beneficial ownership of shares held by the USVP X Funds, except to the extent of any proportionate pecuniary interest therein.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4

Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X with additional rights with respect to the Issuer securities, and may be deemed to have sole voting and dispositive power with respect to the shares. The Reporting Person disclaims beneficial ownership of shares held by the USVP X Funds, except to the extent of any proportionate pecuniary interest therein.